v3.25.4
Revenue (Tables)
12 Months Ended
Dec. 31, 2025
Revenue [abstract]  
Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss

Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:

(EUR’000)

 

2025

 

 

2024

 

 

2023

 

Revenue

 

 

 

 

 

 

 

 

 

Commercial products

 

 

683,572

 

 

 

225,728

 

 

 

178,663

 

Services and clinical supply

 

 

18,008

 

 

 

15,570

 

 

 

21,978

 

Licenses

 

 

5,630

 

 

 

122,343

 

 

 

66,077

 

Milestones

 

 

12,922

 

 

 

 

 

 

 

Total revenue

 

 

720,132

 

 

 

363,641

 

 

 

266,718

 

Specified per geographical area

 

 

 

 

 

 

 

 

 

United States (1)

 

 

546,388

 

 

 

233,115

 

 

 

191,677

 

Europe (2)

 

 

120,946

 

 

 

123,336

 

 

 

869

 

Rest of world (1)

 

 

52,798

 

 

 

7,190

 

 

 

74,172

 

Total revenue

 

 

720,132

 

 

 

363,641

 

 

 

266,718

 

(1)
From 2025, revenue related to the United States has been disclosed separately. Comparatives for the United States and Rest of World have been restated for comparative purposes.
(2)
For the years ended December 31, 2025 and December 31, 2024, Denmark, the country of domicile, contributed with €12.9 million and €95.4 million of revenue, respectively. For the year ended December 31, 2023, no revenue was attributable to Denmark.
Schedule of Revenue Attributable to Commercial Customers by Product

Revenue from sale of commercial products were as follows:

(EUR’000)

 

2025

 

2024

 

2023

Revenue from commercial products

 

 

 

 

 

 

YORVIPATH®

 

477,412

 

28,727

 

SKYTROFA®

 

206,160

 

197,001

 

178,663

Total revenue from commercial products

 

683,572

 

225,728

 

178,663